48 completed. 48 Phase 2, 7 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 48 | Completed 48 |
| Phase 1 | 7 | Completed 7 |
| Phase 3 | 1 | Completed 1 |
Follow Cough: new trials by email Literature Review of Cough trials Research Report on Cough
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy Reconyl for Cough With/Without Sore Throat Reconyl, Placebo tablet of Reconyl - Cough | Phase 2 | Completed | Dexa Medica Group | 60 | 2024-07-23 | 2025-02-07 |
| Cough Reduction in IPF With Nalbuphine ER NAL ER, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Trevi Therapeutics | 165 | 2024-02-06 | 2026-06-26 |
| Refractory Chronic Cough Improvement Via NAL ER (RIVER) NAL ER, Placebo - Refractory Chronic Cough | Phase 2 | Completed | Trevi Therapeutics | 66 | 2023-11-30 | 2026-03-30 |
| QR052107B Tablets in Patients With Subacute Cough of Phase Ⅱ Study QR052107B 100 mg, QR052107B 400 mg, Placebo - Cough | Phase 2 | Completed | Wuhan Createrna Science and Technology Co., Ltd | 270 | 2023-06-21 | 2025-04-10 |
| A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough HRS-2261 oral tablet, Matching placebo to HRS-2261 - Refractory Chronic Cough | Phase 2 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 97 | 2023-03-09 | 2026-01-21 |
| Bolus vs. Continuous IV Lidocaine Against Post-Extubation Cough in Post-Thyroidectomy Patients Lidocaine IV - Cough | Phase 2 | Completed | Universitas Padjadjaran | 40 | 2023-02-02 | 2023-09-22 |
| Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis Orvepitant Maleate, Placebo - Cough, Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Nerre Therapeutics Ltd. | 80 | 2022-08-01 | 2025-11-10 |
| A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough ADX-629, Placebo - Chronic Cough | Phase 2 | Completed | Aldeyra Therapeutics, Inc. | 51 | 2022-04-07 | 2025-02-28 |
| A Study of Efficacy and Safety of AX-8 in Chronic Cough AX-8, Part 1 of the study, Placebo, Part 1 of the study, AX-8, Part 2 of the study - Chronic Cough | Phase 2 | Completed | Axalbion SA | 108 | 2021-08-11 | 2025-09-08 |
| Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN) Hesperidin, Placebo - Covid19, Anosmia | Phase 2 | Completed | Montreal Heart Institute | 216 | 2021-02-18 | 2022-04-08 |
| Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough BLU-5937, Placebo - Refractory Chronic Cough | Phase 2 | Completed | Bellus Health Inc. - a GSK company | 310 | 2020-12-07 | 2021-12-13 |
| The Effects of Salbutamol on Mannitol Induced Cough Responses in Healthy Controls Salbutamol 5mg/mL, Sodium Chloride 0.9% Inhl 3Ml - Cough | Phase 2 | Completed | McMaster University | 20 | 2020-11-30 | 2022-06-16 |
| Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough BAY1817080, Placebo - Refractory and/or Unexplained Chronic Cough | Phase 2 | Completed | Bayer | 310 | 2020-10-02 | 2022-08-18 |
| Efficacy and Safety of Susu Zhike Granules for Treating Acute Cough Due to Common Cold With Cold-cough Syndrome in Children High dose Susu Xiao'er Zhike Granules 1 bag, Middle dose Susu Xiao'er Zhike Granules 1 bag, Extremely-low dose Susu Xiao'er Zhike Granules 1 bag - Cough | Phase 2 | Completed | Tasly Pharmaceutical Group Co., Ltd | 240 | 2020-09-19 | 2024-09-05 |
| Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough Ifenprodil - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Algernon Pharmaceuticals | 20 | 2020-07-29 | 2022-07-19 |
| Evaluation of S-600918 in Adults With Refractory Chronic Cough S-600918, Placebo to S-600918 - Chronic Cough | Phase 2 | Completed | Shionogi | 406 | 2020-02-13 | 2024-03-27 |
| A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough NAL ER, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Trevi Therapeutics | 42 | 2019-10-29 | 2025-05-29 |
| Influence on Cough and Airway Symptoms by Oral Capsaicin Capsicum Oleoresin, Placebos - Cough | Phase 2 | Completed | Vastra Gotaland Region | 55 | 2019-06-01 | 2026-09-01 |
| A Dose Escalation Study of Bradanicline in Refractory Chronic Cough Bradanicline, Placebo - Chronic Cough | Phase 2 | Completed | Attenua, Inc. | 46 | 2018-11-05 | 2019-06-20 |
| Repeat Doses of BAY1902607 in Healthy Males and Proof of Concept in Chronic Cough Patients BAY1902607, Matching placebo, Midazolam - Cough | Phase 1 / Phase 2 | Completed | Bayer | 59 | 2018-05-29 | 2021-02-10 |
Showing 20 of 48. Sign in to see all of them.
Chronic Cough (19) · Idiopathic Pulmonary Fibrosis (5) · Parkinson Disease (3) · Deglutition Disorders (2) · Abdominal Pain (1) · Anosmia (1) · Arthralgia (1) · COVID-19 (1) · Chest Pain (1) · Common Cold (1) · Confusion (1) · Dyspnea (1) · Fever (1) · Headache (1)
Pathological Conditions, Signs and Symptoms (48) · Respiration Disorders (48) · Respiratory Tract Diseases (48) · Signs and Symptoms (48) · Signs and Symptoms, Respiratory (48) · Lung Diseases (8) · Nervous System Diseases (6) · Central Nervous System Diseases (5) · Lung Diseases, Interstitial (5) · Pulmonary Fibrosis (5) · Brain Diseases (4) · Pathologic Processes (4) · Basal Ganglia Diseases (3) · Infections (3)
Gefapixant (8) · Capsaicin (4) · Nalbuphine (3) · 8-(bis(2-chlorophenyl)methyl)-3-(2-pyrimidinyl)-8-azabicyclo(3.2.1)octan-3-ol (2) · ADX-629 (1) · Acetylcysteine (1) · Albuterol (1) · BLU-5937 (1) · DNK 333 (1) · Hesperidin (1) · Lidocaine (1) · Midazolam (1) · Respiratory Physiological Phenomena (1) · Sodium Chloride (1) · Zinc Acetate (1)
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (7) · Merck Sharp & Dohme LLC (4) · University of Florida (4) · Bayer (3) · Trevi Therapeutics (3) · Novartis (2) · Aldeyra Therapeutics, Inc. (1) · Algernon Pharmaceuticals (1) · Attenua, Inc. (1) · Axalbion SA (1) · Bellus Health Inc. - a GSK company (1) · Dexa Medica Group (1) · GlaxoSmithKline (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Hull University Teaching Hospitals NHS Trust (1)
United Kingdom (16) · United States (15) · Canada (7) · Netherlands (6) · Poland (4) · Australia (3) · China (3) · Czechia (3) · Germany (3) · Japan (3) · Hungary (2) · Indonesia (2) · Italy (2) · Spain (2) · Taiwan (2)
Alexandra E. Brandimore, M.A. (1) · Alexandra E. Brandimore, M.A. CCC/SLP (1) · Alyn H Morice (1) · Ardi Zulfariansyah, MD (1) · Christine M Sapienza, Ph.D. (1) · Dewi S Rosdiana, Dr,MD,MKes (1) · Eva Millqvist, MD, PhD (1) · Gail Gauvreau, PhD (1) · Ignatia K Hallis, MD (1)
PMID 15966463, PMID 19029430, PMID 19937046, PMID 25467586, PMID 25811287, PMID 27130637, PMID 28923239, PMID 31023843, PMID 31949115, PMID 32109425, PMID 33825965, PMID 33986030, PMID 34152585, PMID 34697975, PMID 35614875, PMID 35624408, PMID 36345090, PMID 36348054, PMID 36512069, PMID 37041539, PMID 37261531, PMID 38044419, PMID 38320144, PMID 40043302, PMID 40498172, PMID 41569557, PMID 42548348
2015 (4), 2017 (2), 2018 (2), 2016 (1), 2019 (1), R34HL132369 (1)